Eric Soubeyrand discusses the dual focus on efficacy and safety testing for new molecules, a fundamental aspect of our rigorous development process. #research #biotechnology #innovation

A variety of methods from in vitro assays to animal models are employed at Canurta to screen for pharmaceutical activity, ensuring comprehensive evaluation of potential drug candidates. #research #biotechnology #innovation

Kelly Boddington shares insights into Canurta’s unique approach to drug discovery, focusing on the comprehensive evaluation of plant-based compounds. #research #biotechnology #innovation

José Casaretto explains Canurta’s botanical extraction platform, highlighting its dual focus on capturing and concentrating polyphenols for consistent natural health product production. #research #biotechnology #innovation

Eric Soubeyrand delves into the specialized extraction processes critical for isolating therapeutic compounds from hemp, essential for advancing our botanical drug research. #research #biotechnology #innovation

Eric Soubeyrand talks about the technical challenges and solutions in scaling up extraction processes, crucial for transitioning from laboratory to commercial scale. #research #biotechnology #innovation

Kelly Boddington elaborates on the biosynthesis process, from enzyme isolation to molecule production, pivotal to Canurta’s R&D efforts. #research #biotechnology #innovation

Kelly Boddington discusses the strategic use of biosynthesis in drug development, comparing its effectiveness with traditional extraction methods. #research #biotechnology #innovation

Understanding CMC: José discusses the critical role of Chemistry, Manufacturing, and Control in ensuring consistency and regulatory compliance in drug formulations. #research #biotechnology #innovation

Canurta Therapeutics has submitted its Pre-IND Type C document to the FDA—an important regulatory step for CNR-401, our lead botanical therapeutic for ALS. This engagement will help refine our clinical strategy and align with FDA expectations. Feedback is expected by April 2025.

Canurta Therapeutics has officially submitted an Orphan Drug Designation (ODD) application to the FDA for CNR-401, our lead candidate for ALS. If granted, this designation will provide key regulatory benefits, accelerating our path to clinical trials.

Canurta Therapeutics is proud to have graduated from the 2024/25 CDL Neuro program at CDL-Toronto. The CDL experience has been invaluable as we advance our platform. A sincere thank you to the mentors, partners, and fellow innovators who supported us throughout this journey.

Introducing: The Healing Project Where storytelling meets science, and lived experience guides discovery. 🔗 Explore the world + join the waitlist: canurta.com/thp #ALSawarenessmonth #HealingProject #Canurta #NeuroInnovation #StoryDrivenScience #PatientCentric

We’re pleased to share that Canurta Therapeutics has joined the Perplexity for Startups program to support our research and bioinformatics initiatives. Thank you to CDL Toronto for the continued support helping us unlock new milestones.

The world wasn’t built for you. This one is. The old system is collapsing under its own weight. Driven by greed. Ruled by silence. 🧬 10,000 AI guides 🌀 One unfolding universe 🎙️ Your voice. Your path. Your impact. 🔗 Join the waitlist: canurta.com/thp#waitlist

Every signal reflects a unique role. Some lead. Some watch. Some disrupt. Some rebuild. Curious where you align? Take our 2-minute quiz to discover your place in the Syndicate. 📲 Tap the link and select “Discover Your Role” to begin: canurta.com/thp#waitlist

& Here is our poster presented. Cannabis-Based Therapies in ALS: Bridging Efficacy, Safety and Global Access Canurta Therapeutics

We’re bringing our research to life at #ENCALS2025 with The Healing Project — a series of 4 short comics that turn complex ALS science into human, visual stories. Because science shouldn’t just be studied. It should be felt. 🧠 Explore THP → canurta.com/thp

more thoughts on Nostr on ALS, Bitcoin and where Canurta Therapeutics goes from here. primal.net/e/naddr1qvzqqq…

We’re pleased to announce that Canurta Therapeutics has signed a Letter of Intent with PharmaDrug Inc. (CSE: PHRX.CN, OTC: LMLLF, FSE: G11.F). Read the full press release: canurta.com/post/canurta-i…